Its uniform superiority in molecular docking, DFT energies, conformational dynamics, MM/GBSA binding energy, and pIC50 prediction highlights its potential as an HDAC8 inhibitor with selectivity and high potency for the treatment of schistosomiasis. Here, HDAC8 is linked to schistosomiasis.